Autres langues MannKind Corporation

Actions

MNKD

US56400P7069

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 08/10/2026			Varia. 5j.	Varia. 1 janv.
3,420 ^USD	-0,87%		-12,31%	-39,68%

09/09	MannKind Corporation et Rose Pharma Inc concluent un accord de licence et de collaboration pour développer un agoniste du GLP-1 inhalé à action rapide et courte durée pour la gestion du poids	CI
09/09	MannKind et Rose Pharma signent un accord pour le développement d'un médicament contre l'obésité	MT

Autres langues

09/09	MannKind Corporation and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management
09/09	MannKind, Rose Pharma Sign Deal to Develop Weight-Management Drug
09/09	MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management
03/09	MannKind Corporation to Present at Upcoming Investor Conferences
02/09	MannKind to Present at Upcoming Investor Conferences
06/08	MannKind's Diversified Portfolio Seen Leading to Higher Revenue in H2, Wedbush Says
05/08	MannKind: Q2 Earnings Snapshot
05/08	Earnings Flash (MNKD) MannKind Corporation Posts Q2 Adjusted Loss $0.01 per Share
05/08	MannKind Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
05/08	Earnings Flash (MNKD) MannKind Corporation Reports Q2 Revenue $109.4M, vs. FactSet Est of $108.1M
05/08	MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update
30/07	MannKind Top-Line Data From Phase 1b INFLO-1 Study 'Positive,' Wedbush Says
29/07	MannKind Says Phase 1b Study Shows Idiopathic Pulmonary Fibrosis Treatment Generally Safe, Well-Tolerated
29/07	MannKind Corporation Reports Positive Phase 1b INFLO-1 Results And Provides Update On Nintedanib DPI Clinical Development In IPF
29/07	HEALTH ROUNDS-MannKind injection helps heart failure patients avoid ER infusions
29/07	MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF
28/07	MannKind to Report Second Quarter Financial Results and Host Conference Call on August 5, 2026
27/07	MannKind Announces FDA Approval of Furoscix ReadyFlow, the First and Only Autoinjector Delivering IV-Equivalent Diuretic Therapy for the Treatment of Edema in Adults with Heart Failure or Chronic Kidney Disease
24/07	FDA approves Furoscix ReadyFlow for at-home treatment of edema
24/07	MannKind's Furoscix Auto-Injector Approval, Launch Could Provide Strong Upside to 2026 Revenue Expectation, Wedbush Says
24/07	MannKind Corporation announced that it expects to receive $49.999998 million in funding from Frazier Life Sciences Management, LP
24/07	MannKind Corporation Receives U.S. Food and Drug Administration Approval For Furoscix ReadyFlow Autoinjector For Edema Treatment In Adults With Heart Failure Or Chronic Kidney Disease
24/07	MannKind Agrees to $50 Million Private Stock Sale
24/07	MannKind's Furoscix ReadyFlow Injection Approved by US FDA
24/07	MannKind Announces $50 Million Private Placement